155 related articles for article (PubMed ID: 19833261)
1. The pharmacogenetics of statin therapy: when the body aches, the mind will follow.
Rossi JS; McLeod HL
J Am Coll Cardiol; 2009 Oct; 54(17):1617-8. PubMed ID: 19833261
[No Abstract] [Full Text] [Related]
2. SLCO1B1 variants and statin-induced myopathy.
Vladutiu GD; Isackson PJ
N Engl J Med; 2009 Jan; 360(3):304. PubMed ID: 19144951
[No Abstract] [Full Text] [Related]
3. Pharmacogenomics and drug toxicity.
Nakamura Y
N Engl J Med; 2008 Aug; 359(8):856-8. PubMed ID: 18650508
[No Abstract] [Full Text] [Related]
4. [Pharmacogenetic analysis can predict adverse effects of statins].
Garwicz D; Wadelius M
Lakartidningen; 2013 May 7-21; 110(19-20):951-2. PubMed ID: 23745502
[No Abstract] [Full Text] [Related]
5. Researchers worry about myopathy risk for patients taking high-dose simvastatin.
Mitka M
JAMA; 2009 Jan; 301(3):261-2. PubMed ID: 19155447
[No Abstract] [Full Text] [Related]
6. Genetic involvement in statins induced myopathy. Preliminary data from an observational case-control study.
Puccetti L; Ciani F; Auteri A
Atherosclerosis; 2010 Jul; 211(1):28-9. PubMed ID: 20347093
[No Abstract] [Full Text] [Related]
7. Pharmacogenomics and adverse drug reactions: the case of statins.
Giorgi MA; Caroli C; Arazi HC; Di Girolamo G
Expert Opin Pharmacother; 2011 Jul; 12(10):1499-509. PubMed ID: 21568825
[TBL] [Abstract][Full Text] [Related]
8. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
9. [Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy].
Dendramis G
G Ital Cardiol (Rome); 2011 Mar; 12(3):182-5. PubMed ID: 21560474
[TBL] [Abstract][Full Text] [Related]
10. Statins and skeletal muscles toxicity: from clinical trials to everyday practice.
Norata GD; Tibolla G; Catapano AL
Pharmacol Res; 2014 Oct; 88():107-13. PubMed ID: 24835295
[TBL] [Abstract][Full Text] [Related]
11. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR; Lansberg PJ; Zhang L; Miao F; Carter C; Hovingh GK; Visscher H; Jukema JW; Stalenhoef AF; Ross CJ; Carleton BC; Kastelein JJ; Hayden MR
Pharmacogenomics J; 2012 Jun; 12(3):233-7. PubMed ID: 21243006
[TBL] [Abstract][Full Text] [Related]
12. [Use of pharmacogenetic testing to prevent adverse drug reactions during statin therapy].
Rumyantsev NA; Kukes VG; Kazakov RE; Rumyantsev AA; Sychev DA
Ter Arkh; 2017; 89(1):82-87. PubMed ID: 28252633
[TBL] [Abstract][Full Text] [Related]
13. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
[TBL] [Abstract][Full Text] [Related]
14. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
[TBL] [Abstract][Full Text] [Related]
15. The genetics of statin-induced myopathy.
Ghatak A; Faheem O; Thompson PD
Atherosclerosis; 2010 Jun; 210(2):337-43. PubMed ID: 20042189
[TBL] [Abstract][Full Text] [Related]
16. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.
Generaux GT; Bonomo FM; Johnson M; Doan KM
Xenobiotica; 2011 Aug; 41(8):639-51. PubMed ID: 21425956
[TBL] [Abstract][Full Text] [Related]
17. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy.
Couvert P; Chapman MJ; Carrié A
Pharmacogenomics; 2011 Feb; 12(2):137-9. PubMed ID: 21332305
[No Abstract] [Full Text] [Related]
18. Pharmacogenetics and statin-related myopathy: what do we know?
Turner RM; Radman I; Bozina N; Alfirevic A
Pharmacogenomics; 2020 Aug; 21(12):821-825. PubMed ID: 32723135
[No Abstract] [Full Text] [Related]
19. Predicting response to statins by pharmacogenetic testing.
Gelissen IC; Brown AJ
Pharmacogenomics; 2012 Aug; 13(11):1223-5. PubMed ID: 22920392
[No Abstract] [Full Text] [Related]
20. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
